Biohaven pharmaceutical holding company completes enrollment in phase 3 generalized anxiety disorder trial of troriluzole

Biohaven pharmaceutical holding company ltd. announced that it has completed enrollment in its pivotal phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized anxiety disorder (gad). this multicenter, randomized, placebo-controlled, trial enrolled over 880 patients in less than nine months. gad is a chronic and long-lasting disorder in which a person has uncontrollable, excessive anxiety and worry and is often associated with significant functional impairment. the primary outcome measure in this 8-week gad trial with troriluzole is the change in a patient's score on the hamilton anxiety rating scale (ham-a), a scale designed to assess the severity and type of symptoms in patients with gad. the ham-a is a widely used and validated scale that has served as the primary outcome measure to obtain approval in gad both in the united states and globally. the trial will also assess the safety, tolerability and pharmacokinetics of troriluzole. troriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. the primary mode of action of troriluzole is reducing synaptic levels of glutamate. troriluzole increases glutamate uptake from the synapse, by augmenting the expression and function of excitatory amino acid transporters (i.e., eaat2) located on glial cells that play a key role in clearing glutamate from the synapse.
BHVN Ratings Summary
BHVN Quant Ranking